Puma Biotech (PBYI) Tops Q4 EPS by 95c, Beat on Revenues

Note: EPS may not be comparable

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($1.03), $0.95 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.01 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
• Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance